Previous 10 |
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering PR Newswire VANCOUVER, BC, Nov. 16, 2020 VANCOUVER, BC , Nov. 16, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-st...
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results PR Newswire VANCOUVER, BC, Nov. 13, 2020 VANCOUVER, BC , Nov. 13, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...